Which has better earnings & valuation, BLTE or TRLV?

Trulieve Cannabis has higher revenue and earnings than Belite Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Belite Bio N/A N/A -$77.61M -$2.73 N/A Trulieve Cannabis $1.14B 2.07 N/A N/A N/A

Is BLTE or TRLV more profitable?

Trulieve Cannabis' return on equity of 0.00% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -11.84% -11.62% Trulieve Cannabis N/A N/A N/A

Which has higher valuation & earnings, LNTH or TRLV?

Lantheus has higher revenue and earnings than Trulieve Cannabis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.22 $233.56M $4.14 24.09 Trulieve Cannabis $1.14B 2.07 N/A N/A N/A

Does the media prefer LNTH or TRLV?

In the previous week, Lantheus had 8 more articles in the media than Trulieve Cannabis. MarketBeat recorded 13 mentions for Lantheus and 5 mentions for Trulieve Cannabis. Lantheus' average media sentiment score of 0.50 beat Trulieve Cannabis' score of 0.27 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 2 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Trulieve Cannabis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, AMRX or TRLV?

Amneal Pharmaceuticals has higher revenue and earnings than Trulieve Cannabis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amneal Pharmaceuticals $3.02B 2.09 $72.06M $0.49 40.35 Trulieve Cannabis $1.14B 2.07 N/A N/A N/A

Does the media refer more to AMRX or TRLV?

In the previous week, Amneal Pharmaceuticals had 7 more articles in the media than Trulieve Cannabis. MarketBeat recorded 12 mentions for Amneal Pharmaceuticals and 5 mentions for Trulieve Cannabis. Amneal Pharmaceuticals' average media sentiment score of 0.72 beat Trulieve Cannabis' score of 0.27 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trulieve Cannabis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, LQDA or TRLV?

Trulieve Cannabis has higher revenue and earnings than Liquidia. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $450.91M 13.58 -$68.92M $1.37 49.95 Trulieve Cannabis $1.14B 2.07 N/A N/A N/A

Does the media refer more to LQDA or TRLV?

In the previous week, Trulieve Cannabis had 2 more articles in the media than Liquidia. MarketBeat recorded 5 mentions for Trulieve Cannabis and 3 mentions for Liquidia. Liquidia's average media sentiment score of 0.48 beat Trulieve Cannabis' score of 0.27 indicating that Liquidia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trulieve Cannabis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, DFTX or TRLV?

Trulieve Cannabis has higher revenue and earnings than Definium Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A Trulieve Cannabis $1.14B 2.07 N/A N/A N/A

Is DFTX or TRLV more profitable?

Trulieve Cannabis' return on equity of 0.00% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Definium Therapeutics N/A -84.01% -63.66% Trulieve Cannabis N/A N/A N/A

Does the media favor DFTX or TRLV?

In the previous week, Definium Therapeutics had 1 more articles in the media than Trulieve Cannabis. MarketBeat recorded 6 mentions for Definium Therapeutics and 5 mentions for Trulieve Cannabis. Trulieve Cannabis' average media sentiment score of 0.27 beat Definium Therapeutics' score of 0.03 indicating that Trulieve Cannabis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Trulieve Cannabis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Trulieve Cannabis (TRLV) Competitors

$12.22 -0.05 (-0.37%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$12.22 -0.01 (-0.07%)

As of 09/25/2026 07:57 PM Eastern

Compare

TRLV vs. BLTE, LNTH, AMRX, LQDA, and DFTX

Should you buy Trulieve Cannabis stock or one of its competitors? Trulieve Cannabis's main competitors and comparable companies include Belite Bio (BLTE), Lantheus (LNTH), Amneal Pharmaceuticals (AMRX), Liquidia (LQDA), and Definium Therapeutics (DFTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Trulieve Cannabis compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Trulieve Cannabis (NYSE:TRLV) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

In the previous week, Trulieve Cannabis had 4 more articles in the media than Belite Bio. MarketBeat recorded 5 mentions for Trulieve Cannabis and 1 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.82 beat Trulieve Cannabis' score of 0.27 indicating that Belite Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Belite Bio	Very Positive
Trulieve Cannabis	Neutral

0.5% of Belite Bio shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Comparatively, 3.8% of Trulieve Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Trulieve Cannabis' return on equity of 0.00% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Trulieve Cannabis	N/A	N/A	N/A

Trulieve Cannabis has higher revenue and earnings than Belite Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Trulieve Cannabis	$1.14B	2.07	N/A	N/A	N/A

Belite Bio currently has a consensus price target of $218.73, suggesting a potential upside of 30.72%. Trulieve Cannabis has a consensus price target of $15.00, suggesting a potential upside of 22.71%. Given Belite Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Belite Bio is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Belite Bio beats Trulieve Cannabis on 6 of the 10 factors compared between the two stocks.

How does Trulieve Cannabis compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Trulieve Cannabis (NYSE:TRLV) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

Lantheus has higher revenue and earnings than Trulieve Cannabis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.22	$233.56M	$4.14	24.09
Trulieve Cannabis	$1.14B	2.07	N/A	N/A	N/A

In the previous week, Lantheus had 8 more articles in the media than Trulieve Cannabis. MarketBeat recorded 13 mentions for Lantheus and 5 mentions for Trulieve Cannabis. Lantheus' average media sentiment score of 0.50 beat Trulieve Cannabis' score of 0.27 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	2 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Trulieve Cannabis	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has a net margin of 17.69% compared to Trulieve Cannabis' net margin of 0.00%. Lantheus' return on equity of 28.10% beat Trulieve Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Trulieve Cannabis	N/A	N/A	N/A

99.1% of Lantheus shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 3.8% of Trulieve Cannabis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lantheus presently has a consensus target price of $108.11, suggesting a potential upside of 8.39%. Trulieve Cannabis has a consensus target price of $15.00, suggesting a potential upside of 22.71%. Given Trulieve Cannabis' higher possible upside, analysts plainly believe Trulieve Cannabis is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Lantheus beats Trulieve Cannabis on 10 of the 12 factors compared between the two stocks.

How does Trulieve Cannabis compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Trulieve Cannabis (NYSE:TRLV) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Amneal Pharmaceuticals currently has a consensus price target of $21.00, suggesting a potential upside of 6.22%. Trulieve Cannabis has a consensus price target of $15.00, suggesting a potential upside of 22.71%. Given Trulieve Cannabis' higher possible upside, analysts clearly believe Trulieve Cannabis is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Amneal Pharmaceuticals had 7 more articles in the media than Trulieve Cannabis. MarketBeat recorded 12 mentions for Amneal Pharmaceuticals and 5 mentions for Trulieve Cannabis. Amneal Pharmaceuticals' average media sentiment score of 0.72 beat Trulieve Cannabis' score of 0.27 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trulieve Cannabis	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amneal Pharmaceuticals has a net margin of 5.05% compared to Trulieve Cannabis' net margin of 0.00%. Trulieve Cannabis' return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Trulieve Cannabis	N/A	N/A	N/A

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 3.8% of Trulieve Cannabis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Amneal Pharmaceuticals has higher revenue and earnings than Trulieve Cannabis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	2.09	$72.06M	$0.49	40.35
Trulieve Cannabis	$1.14B	2.07	N/A	N/A	N/A

Summary

Amneal Pharmaceuticals beats Trulieve Cannabis on 10 of the 12 factors compared between the two stocks.

How does Trulieve Cannabis compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Trulieve Cannabis (NYSE:TRLV) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

Trulieve Cannabis has higher revenue and earnings than Liquidia.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$450.91M	13.58	-$68.92M	$1.37	49.95
Trulieve Cannabis	$1.14B	2.07	N/A	N/A	N/A

In the previous week, Trulieve Cannabis had 2 more articles in the media than Liquidia. MarketBeat recorded 5 mentions for Trulieve Cannabis and 3 mentions for Liquidia. Liquidia's average media sentiment score of 0.48 beat Trulieve Cannabis' score of 0.27 indicating that Liquidia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Trulieve Cannabis	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Liquidia has a net margin of 30.74% compared to Trulieve Cannabis' net margin of 0.00%. Liquidia's return on equity of 149.65% beat Trulieve Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Trulieve Cannabis	N/A	N/A	N/A

64.5% of Liquidia shares are owned by institutional investors. 25.6% of Liquidia shares are owned by company insiders. Comparatively, 3.8% of Trulieve Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Liquidia presently has a consensus target price of $98.08, suggesting a potential upside of 43.33%. Trulieve Cannabis has a consensus target price of $15.00, suggesting a potential upside of 22.71%. Given Liquidia's stronger consensus rating and higher probable upside, equities analysts plainly believe Liquidia is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Liquidia beats Trulieve Cannabis on 11 of the 13 factors compared between the two stocks.

How does Trulieve Cannabis compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Trulieve Cannabis (NYSE:TRLV) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

In the previous week, Definium Therapeutics had 1 more articles in the media than Trulieve Cannabis. MarketBeat recorded 6 mentions for Definium Therapeutics and 5 mentions for Trulieve Cannabis. Trulieve Cannabis' average media sentiment score of 0.27 beat Definium Therapeutics' score of 0.03 indicating that Trulieve Cannabis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Trulieve Cannabis	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

27.9% of Definium Therapeutics shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by insiders. Comparatively, 3.8% of Trulieve Cannabis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Definium Therapeutics currently has a consensus price target of $64.88, suggesting a potential upside of 79.36%. Trulieve Cannabis has a consensus price target of $15.00, suggesting a potential upside of 22.71%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Definium Therapeutics is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	3.00
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Trulieve Cannabis has higher revenue and earnings than Definium Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Trulieve Cannabis	$1.14B	2.07	N/A	N/A	N/A

Trulieve Cannabis' return on equity of 0.00% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Trulieve Cannabis	N/A	N/A	N/A

Summary

Definium Therapeutics beats Trulieve Cannabis on 6 of the 11 factors compared between the two stocks.

Get Trulieve Cannabis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRLV vs. The Competition

Export

Metric	Trulieve Cannabis	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$2.35B	$12.67B	$7.33B	$23.00B
Dividend Yield	N/A	2.63%	2.52%	3.68%
P/E Ratio	N/A	797.38	275.82	28.00
Price / Sales	2.07	785.09	604.28	21.01
Price / Cash	N/A	89.30	79.52	41.27
Price / Book	N/A	10.54	10.44	4.66
Net Income	N/A	$2.85B	$3.51B	$1.07B
7 Day Performance	9.81%	-1.10%	-1.31%	-1.12%
1 Month Performance	10.35%	-3.06%	-4.61%	-5.10%
1 Year Performance	N/A	1.28%	15.01%	7.73%

Trulieve Cannabis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRLV Trulieve Cannabis	2.959 of 5 stars	$12.22 -0.4%	$15.00 +22.7%	N/A	$2.35B	$1.14B	N/A	5,000	News Coverage Short Interest Increase
BLTE Belite Bio	3.7723 of 5 stars	$175.35 +1.1%	$218.73 +24.7%	+139.1%	$6.98B	N/A	N/A	41	Positive News
LNTH Lantheus	3.2867 of 5 stars	$100.00 -0.3%	$108.11 +8.1%	+97.1%	$6.55B	$1.54B	24.15	1,193	News Coverage Analyst Upgrade
AMRX Amneal Pharmaceuticals	3.5383 of 5 stars	$19.50 -3.3%	$20.14 +3.3%	+102.8%	$6.44B	$3.02B	39.80	8,500	Analyst Forecast
LQDA Liquidia	3.601 of 5 stars	$68.64 +3.3%	$98.08 +42.9%	+213.9%	$5.95B	$158.32M	50.10	216	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:TRLV) was last updated on 9/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trulieve Cannabis (TRLV) Competitors

TRLV vs. BLTE, LNTH, AMRX, LQDA, and DFTX

How does Trulieve Cannabis compare to Belite Bio?

Summary

How does Trulieve Cannabis compare to Lantheus?

Summary

How does Trulieve Cannabis compare to Amneal Pharmaceuticals?

Summary

How does Trulieve Cannabis compare to Liquidia?

Summary

How does Trulieve Cannabis compare to Definium Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRLV vs. The Competition

Trulieve Cannabis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trulieve Cannabis (TRLV) Competitors

TRLV vs. BLTE, LNTH, AMRX, LQDA, and DFTX

How does Trulieve Cannabis compare to Belite Bio?

Does the media prefer BLTE or TRLV?

Do institutionals & insiders hold more shares of BLTE or TRLV?

Is BLTE or TRLV more profitable?

Which has better earnings & valuation, BLTE or TRLV?

Do analysts rate BLTE or TRLV?

Summary

How does Trulieve Cannabis compare to Lantheus?

Which has higher valuation & earnings, LNTH or TRLV?

Does the media prefer LNTH or TRLV?

Is LNTH or TRLV more profitable?

Do institutionals and insiders hold more shares of LNTH or TRLV?

Do analysts rate LNTH or TRLV?

Summary

How does Trulieve Cannabis compare to Amneal Pharmaceuticals?

Do analysts rate AMRX or TRLV?

Does the media refer more to AMRX or TRLV?

Is AMRX or TRLV more profitable?

Do insiders and institutionals hold more shares of AMRX or TRLV?

Which has preferable valuation and earnings, AMRX or TRLV?

Summary

How does Trulieve Cannabis compare to Liquidia?

Which has stronger earnings & valuation, LQDA or TRLV?

Does the media refer more to LQDA or TRLV?

Is LQDA or TRLV more profitable?

Do insiders & institutionals hold more shares of LQDA or TRLV?

Do analysts rate LQDA or TRLV?

Summary

How does Trulieve Cannabis compare to Definium Therapeutics?

Does the media favor DFTX or TRLV?

Do insiders and institutionals have more ownership in DFTX or TRLV?

Do analysts prefer DFTX or TRLV?

Which has better earnings and valuation, DFTX or TRLV?

Is DFTX or TRLV more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRLV vs. The Competition

Trulieve Cannabis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools